ArticleJournal of food science2025
Extracellular Vesicle-Like Nanoparticles Present in Fermented Botanical Products Suppress Fat Absorption in the Gut.
Article in Journal of food science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extracellular vesicle-like nanoparticles from Lactobacillus delbrueckii protect keratinocyte barrier function with involvement of TRPV4 signaling.World journal of microbiology & biotechnology · 2026Article
- Surface Layer-Associated Protein on Nanoparticles from Lactobacillus helveticus Enhances the Response to LPS in RAW264.7 Cells.Current microbiology · 2026Article
- Extracellular Vesicle-Like Nanoparticles Present in Fermented Botanical Products Suppress Fat Absorption in the Gut.Journal of food science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fermented botanical product (FBP) is a complex, primarily plant-based fermented food that has been popular among consumers for many years. Although FBP may modulate gastrointestinal function, the responsible factors and precise mechanisms remain unclear and speculative. Extracellular vesicles (EVs) have gained widespread attention as a novel signaling system, not only in animals but also in plants and microorganisms. Here, we report that FBP contains EV-like nanoparticles composed of protein complexes originating from various lactic acid bacteria. When mice consumed the EV-like nanoparticle-enriched fraction of FBP as a beverage for three weeks, their body weight gain was reduced by up to approximately 10%, particularly in those fed a high-fat/high-sucrose (HF/HS) diet. Although the HF/HS diet induced colonic atrophy in mice, the ingestion of the EV-like nanoparticles-enriched fraction of FBP increased lipid efflux in feces by more than two-fold and improved the pathological images of the colon. In vitro experiments on lipase activity suggested lipase inhibitory activity in the EV-like nanoparticle-enriched fraction of FBP. Compound analyses revealed that ferulic acid was enriched in the EV-like nanoparticle fraction and inhibited lipase activity in vitro. The biological effects observed in this study were attenuated by reducing the amount of EV-like nanoparticles using a polytetrafluoroethylene (PTFE) membrane. However, the slight reduction (not statistically significant) in bioactivity in the PTFE-treated group compared with the polyether sulfone (PES) treated group, despite a marked decrease in ferulic acid content, suggests the possible involvement of additional molecules beyond EV-like nanoparticles in this fraction. These findings indicate that FBP may serve as a potential therapeutic option for obesity and gastric symptoms. PRACTICAL APPLICATIONS: Extracellular vesicle-like nanoparticles in FBP may support health by alleviating obesity through the suppression of excessive intestinal lipid uptake. These findings suggest that FBP could be developed into a functional food or supplement for individuals who frequently consume high-fat diets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.